Localized Modulation of Immune
and Inflammatory Responses for
Treatment of Diabetes and Other Conditions
Alginate Encapsulated Insulin-Producing Cells Protected from Immune System Rejection
ABOUT US
We have a broad portfolio (8 patent families) of issued and pending applications covering multiple indications/applications but for Alginate Encapsulated Insulin-Producing Cells Protected from Immune System Rejection. Our cellular applications initially targeted to treatment of Diabetes Mellitus Type 1 through pancreatic islet cell transplantation and other indications include treatment of diabetic foot ulcers and peritoneal adhesions
ABOUT OUR PLATFORM TECHNOLOGY
Our CXCL12 platform technology was exclusively licensed from Massachusetts General Hospital in 2013. Our platform is broadly divided into cellular and non-cellular product lines and includes feasibility and long-term maintenance of transplanted human islet cells established in non human primate models
Cell Transplantation Program For Type 1 Diabetes
Funded by and developed in partnership with the JDRF
Diabetes Allotransplant Experiments
n Non-Human Primates (NHP) are On-Going
Identifying the optimal β-stem cell partner for clinical studies
DIABETES MARKET SCOPE
The global treatment market for type 1 diabetes will expand from $6.6b in 2013 to an estimated $13.6b by 2023.
From 2000-2015 diabetes costs in the U.S. nearly doubled, from $12.05 to $23.35 million.
The number of adults living with diabetes has almost quadrupled since 1980.
\
Diabetes is one of the leading causes of death in the world, and in 2012, was the direct cause of 1.5 million deaths.
Non-Cellular Program Addresses Two Conditions
TREATMENT OF DIABETIC FOOT ULCERS
DFUs are a significant financial burden to health care systems and significantly
impact the Quality of Life indices for patients and their families
PREVENTION OF POST-PERITONEAL SURGERY ADHESIONS
An unmet medical need with more than 10 million patients at risk
in the US and 25 million patients globally
DFU MARKET SCOPE
Between 1.0 - 3.5 million diabetic patients in the United States have a history of foot ulceration
ADHESIONS MARKET SCOPE
Demand for adhesion barriers surgeries poised to grow at a CAGR of 9.2% between 2016 and 2024.
The estimated global market of greater than US$ $USD2.7 Billion by 2020
North America market is expected to be US$ 1.6 Billion during 2016 to 2026